DrugBank is a pharmaceutical knowledge base that is enabling major advances across the data-driven medicine industry.

The knowledge base consists of proprietary authored content describing clinical level information about drugs such as side effects and drug interactions, as well as molecular level data such as chemical structures and what proteins a drug interacts with. DrugBank offers a suite of products powered by the DrugBank Platform and has customers located around the world crossing multiple industries including precision medicine, electronic health records, drug development and regulatory agencies. DrugBank also provides DrugBank Online as a free-to-access resource for academic research and is used by millions of pharmacists, pharmacologists, health professionals and pharmaceutical researchers every year.

DrugBank for Commercial Use
Cite DrugBank
About DrugBank
DrugBank top drugs
  1. Morphine
  2. Acetaminophen
  3. Acetylsalicylic acid
  4. Codeine
  5. Salbutamol
  6. Oxycodone
Featured Info
COVID-19 Information Dashboard

We've put together a COVID-19 Information Dashboard, to provide a comprehensive summary of relevant COVID-19 research, in an effort to help researchers find the information they need quickly and effectively.

View the Dashboard
Featured Drug
Db14761

Remdesivir

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated in vitro activity against the Arenaviridae, Flaviviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, and Coronaviridae viral families. Remdesivir activity against the Coronaviridae family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] Based on aggregate data, remdesivir was granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020. The FDA subsequently granted full approval for remdesivir as a COVID-19 treatment on October 22, 2020, while simultaneously updating the EUA to cover those patients not included under the approved indication. Remdesivir is currently marketed under the trademark name VEKLURY® by Gilead Sciences Inc.

DrugBank Online is offered to the public as a free to access resource.

DrugBank Online is offered to the public as a free-to-access resource. Use and re-distribution of the content of DrugBank Online or the DrugBank Data, in whole or in part, for any purpose requires a license. Academic users may apply for a free license for certain use cases and all other users require a paid license.

How to Cite DrugBank
Contact Sales
Apply for Academic License